FDA Approval Alert: The Need-to-Know | Amivantamab/Lazertinib in Advanced EGFR+ NSCLC
In August 2024, the FDA approved amivantamab-vmjw in combination with lazertinib as frontline therapy for patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer.